Beacon Therapeutics

Beacon Therapeutics was launched in 2023 by Syncona as a gene therapy biotech company whose purpose is to improve or restore vision in patients with various retinal diseases that eventually lead to blindness. They use a target generation technology platform to identify and screen new therapeutic targets. The foundation of Beacon Therapeutics originates from co-founder Dr. Robert MacLaren’s ground-breaking work in ophthalmology at the University of Oxford.

Jobs: